CALL TO ACTION: Protect cBHT!

Published October 7, 2020

FDA is threatening cBHT restrictions. Urge your member of Congress to weigh in.

Compounders and other pharmacy professionals!

In the wake of that flawed NASEM study, FDA has said it will consider restricting compounded hormone therapy. It’s likely that cBHT patients are a good share of your business, and that the therapies you prepare have helped those patients immensely.

Although FDA has not yet proposed specific restrictions, NOW is the time to begin to educate your member of Congress about cBHT — and to ask them to sign on to a joint congressional letter to FDA raising concerns about the NASEM cBHT study that FDA funded.

Ask your U.S. House member to sign the joint letter to FDA sponsored by Reps. Pocan, Herrera-Beutler, Cuellar, and Roe.

We’ve made it easy for you to reach your representative. Click the button below and you’ll find a pre-written message — which you may customize as you wish — and send to your elected officials. Takes less than two minutes!

Thank you for your support. And if you can share your testimonial about how cBHT has helped you or your patients, please do! We have an easy form at A4PC.org/cbhtandme. We’ll be using those testimonials in our efforts to prevent FDA from restricting your patients’ healthcare!